Immune Therapeutics Announces Special Investor Conference Call to Discuss 2017 Outlook

Immune Therapeutics Announces Special Investor Conference Call to Discuss 2017 Outlook
0 27 January 2017

ORLANDO, Fla., Jan. 27, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced that it will hold a special investor conference call to discuss the Company‚Äôs recent operating highlights and its financial and operational outlook for 2017. The conference call will follow a press release that will be issued pre-market on January 30, 2017 summarizing these topics.
WHAT: IMUN 2016 Highlights and 2017 Outlook conference call

WHEN: Monday, January 30, 2017 at 11:00 am ET, 8 am PT

WHO: Call and Q&A session will be hosted by Noreen Griffin, Chief Executive Officer,
and Peter Aronstam, Chief Financial Officer, of Immune Therapeutics, Inc.

HOW: (Toll Free) (866) 682-6100, (International): (862) 255-5401

WEB-CAST: IMUN Outlook for 2017 Investor Conference Call

Please call in 10 minutes prior to the conference call to assure you are placed into the call on time.

REPLAY INFO
Replay Number (Toll Free): 877-481-4010
Replay Number (International): 919-882-2331
Replay ID: 10214
Teleconference Replay Available Until: Feb 13, 2017 at 11:59 PM

About the Company
Immune Therapeutics is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapies with a focus of providing such therapies in emerging nations. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory and autoimmune diseases.

The Company’s proprietary technology, therapies and patents include the treatment of a wide range of cancers. Its most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone product (LDN) or LodonalTM, which have been shown to stimulate the immune system even in patients with advanced cancer.

Forward Looking Statements

This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.

Investor/Media Contact:
Kevin Yamano
Investor Relations Partners
Phone: 818-280-6800
kyamano@irpartnersinc.com

Source: GlobeNewswire (January 27, 2017 – 3:40 PM EST)

Posted in Press Releases by admin